Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report

Nan Luo; Lingyuan Zhong; Nana Luo; Qiuyue Wang; Tianhao Li; Pingsheng Hao

doi:10.2147/JIR.S412418

Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report

J Inflamm Res. 2023 May 19:16:2167-2172. doi: 10.2147/JIR.S412418. eCollection 2023.

Authors

Nan Luo¹, Lingyuan Zhong¹, Nana Luo¹, Qiuyue Wang¹, Tianhao Li¹, Pingsheng Hao¹

Affiliation

¹ Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.

Abstract

Psoriasis is a recurring systemic disease that can be treated with biologics to some effect. However, precisely targeting inflammatory mediators may disrupt immune system homeostasis and lead to new conditions. Here, we report a case of psoriasiform dermatitis (PsoD) caused by IL-17 inhibitors (IL-17i) namely secukinumab treatment for psoriasis. This case proposes an effective use of Janus kinase inhibitor (JAKi) tofacitinib to confront lesions induced by IL-17i. This is the first case report of PsoD caused by secukinumab treated with tofacitinib.

Keywords: IL-17 inhibitors; Janus kinase inhibitor; Th1-Th2 balance; psoriasiform dermatitis; tofacitinib.

Publication types

Case Reports

Grants and funding

This work was supported by the Program of Health Commission of Sichuan Province (Grant No. Chuan-2021-505). And preparation and development of medicated bath Wupi effervescent tablets for senile skin pruritus.